scholarly journals T memory stem cells after allogeneic haematopoietic cell transplantation: unique long‐term kinetics and influence of chronic graft‐versus‐host disease

2019 ◽  
Vol 186 (6) ◽  
pp. 866-878 ◽  
Author(s):  
Koji Jimbo ◽  
Takaaki Konuma ◽  
Eri Watanabe ◽  
Chisato Kohara ◽  
Motoko Mizukami ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host ◽  
Haematopoietic Cell ◽  
Allogeneic Haematopoietic Cell Transplantation

Long Term Survival in Refractory Leukemia Patient Treated with Related HLA Haploidentical Stem Cell Transplantation

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4411-4411
Author(s):  
Bingyi Wu ◽  
Guo Kunyuan ◽  
Jing Wu
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Term Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Disease Free

Abstract Objective: To assess the long term survival of patients with refractory leukemia treated by HLA haploidentical stem cell transplantation. Methods To analysis the outcomes of 48 cases patients with refractory leukemia underwent HLA haploidentical stem cell transplantations from August, 1998 to May, 2008. The median age was 16 years old (7–52 years old). Patients received stem cells from their parants, daughter, son, and sibling donors. Twelve patients received three HLA locus mismatched stem cells and twenty patients received two HLA locus mismatched donors stem cells. Sixteen patients were grafted one HLA mismatched donors stem cells. The conditioning regime consisted of fludara (25mg/m2 × 5d), busulfan (4mg/kg × 4d) and cyclophosphamide (60mg/kg × 2d). Median dose of rabbit anti-human lymphocyte globulin (5mg/kg × 5d) was added. CSA combined with short course of MTX were used for prophylaxis GVHD. A median dose of 6.0 × 108/kg(3–9 ×108/kg) mono-nucleated cells was grafted. The mean CD34+ cells number was 5.5 × 106/kg (3–6.5 × 106/kg) Results Forty-seven patients were successfully to be engraftment and one failed to be engraftment. The median time of white cells and platelet reconstitution was 14 days (11–20 days) and 18 days (14–20) respectively. Severe acute graft versus host disease occurred in seven patients, and six died. Seven patients suffered from intensive chronic graft versus host disease and four died with fungus infection. Seven patients relapsed and died. The median relapse time was 6 months (3 months to 24 months). Three patients died from severe diarrhea with CMV infection. Four patients died from intensive chronic graft versus host disease. Twenty patients are still survival and disease free with high karnofsky performance scores. The disease free survival is 45 percent as follow up 3 years (1 to 7 years). Conclusion: HLA haploidentical peripheral blood stem cell transplantation may be an effect therapy to refractory leukemia. And some refractory leukemia patients could benefit from HLA haploidentical peripheral blood stem cell transplantation.

Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa

Blood ◽  
2010 ◽  
Vol 116 (10) ◽  
pp. 1803-1806 ◽  
Author(s):  
Faisal M. Khan ◽  
Sarah Sy ◽  
Polly Louie ◽  
Alejandra Ugarte-Torres ◽  
Noureddine Berka ◽  
...  
Keyword(s):  
Genomic Instability ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Host Disease ◽  
Graft Versus Host ◽  
Allogeneic Hct ◽  
History Of

Abstract Genomic instability (GI) of cells may lead to their malignant transformation. Carcinoma after hematopoietic cell transplantation (HCT) frequently involves some (eg, oral) but not other (eg, nasal) epithelia. We examined GI in oral and nasal mucosal specimens from 105 subjects, including short-term (7-98 days, n = 32) and long-term (4-22 yrs, n = 25) allogeneic HCT survivors. Controls included autologous HCT survivors (n = 11), patients treated with chemotherapy without HCT (n = 9) and healthy controls (n = 27). GI was detected in 60% oral versus only 4% nasal specimens in long-term allogeneic HCT survivors (P < .001). None of the controls showed GI. In oral specimens, GI was significantly associated with history of oral chronic graft-versus-host disease (cGVHD). We conclude that GI after HCT is frequent in some (oral) but rare in other (nasal) epithelia. This may explain why some epithelia (especially those involved with cGVHD) are prone to develop cancer.

scholarly journals Allogeneic Stem Cell Transplantation Combined with Mesenchymal Stem Cells Transfusion in Primary Myelofibrosis-a Single-Center Retrospective Study

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2054-2054
Author(s):  
Qingyuan Wang ◽  
Limin Liu ◽  
Huifen Zhou ◽  
Miao Miao ◽  
Depei Wu
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Graft Versus Host Disease ◽  
Primary Myelofibrosis ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host

Background: There are multiple treatment options that may provide symptom relief and improvement in survival in patients with primary myelofibrosis. However, allogeneic stem cell transplantation (ASCT) remains the only potentially curative option. The use and effectiveness of ASCT are limited by lethal complications, i.e., engraftment failure, acute and chronic graft-versus-host disease. Several clinical trials have used mesenchymal stem cells (MSCs) in ASCT to prevent hematopoietic stem cell (HSC) engraftment failure and to control graft versus host disease (GVHD). Objective :To evaluate the efficacy of MSCs transfusion in patients with primary myelofibrosis after allogeneic hematopoietic stem cell transplantation. Methods :The clinical data of 11 patients with primary myelofibrosis underwent ASCT and MSCs transfusion were retrospectively analyzed. Results:Among the 11 patients, 5 were male and 6 were female, with a median age of 34(20-48) years. Risk profile according the DIPSS-plus score was intermediate-1 risk(n=2) , intermediate-2 risk (n=2), and high risk (n=7). 7 of 11 patients were MF-3 and 4 cases were MF-2. Severe splenomegaly before transplantation were observed in 8 patients. Six patients were treated with ruxolitinib prior to ASCT. Among the 11 patients, 3 patients received HLA-identical sibling-ASCT, 2 received unrelated donor-ASCT and 6 received haploid ASCT from related donors. Median age of donor is 34 years old (range,20~48years old). All patients received myeloablative BuCy conditioning regime and GVHD prophylaxis consisted of cyclosporine A and MTX. Further GVHD prophylaxis consisted of ATG and MMF. All but 2 patients received peripheral blood stem cells (PBST)as graft source, the rest graft source were bone marrow (BM) plus PBST. The median number of transplanted NC cells was 12.27 (2.63 ~ 16.75) *10E8/Kg, and CD34+ cells was 5 (4.2 ~ 7.8) *10E6/Kg. BM-derived MSCs were transfused at +7d after stem cell transplantation. The median MSC infusion number was 6.5*10E6(6 ~ 65*10E6). All patients obtained hematopoietic reconstruction after transplantation, and chimerism analysis by short tandem repeat(STR) suggested complete chimerism. The median time to leukocyte engraftment was 12(range,11 ~ 20days) days and the median time to platelet engraftment was 18 days (range, 8-145 days). Leukocyte was continuously implanted in all patients whereas platelet was continuously implanted in 8 patients. Three patients did not experience any acute graft-versus-host disease (GVHD) .4 patients developed grade 1-2 acute GVHD and 4 developed grade 3-4 acute GVHD. Chronic GVHD was seen in 6 patients which were all limited disease. The median follow-up time was 24.3(1.7 ~ 48 months) months, and the expected 3-year overall survival rate was 61.4%. During the follow-up period, none relapse were observed.Four patients died, 2 of which died early after transplantation (2 months and 1.7 months). The causes of death were thrombotic microangiopathy and immunological cerebrovascular inflammation (this patient had congenital abnormalities of cerebrovascular development and had a long history of repeated epilepsy before transplantation). The other 2 patients died late after transplantation (12 months and 6.4 months) due to heart failure (the patient was with persistent atrial fibrillation before transplantation) and pulmonary infection. Conclusion: Our results demonstrated that MSCs transfusion combined with allogeneic hematopoietic stem cell transplantation is an effective treatment for primary myelofibrosis. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document